List of Excipients in Branded Drug PROTOPIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LEO Pharma Inc	PROTOPIC	tacrolimus	50222-203	.ALPHA.-TOCOPHEROL, DL-
LEO Pharma Inc	PROTOPIC	tacrolimus	50222-203	BUTYLATED HYDROXYTOLUENE
LEO Pharma Inc	PROTOPIC	tacrolimus	50222-203	MINERAL OIL
LEO Pharma Inc	PROTOPIC	tacrolimus	50222-203	PARAFFIN
LEO Pharma Inc	PROTOPIC	tacrolimus	50222-203	PETROLATUM

Protopic Excipient Strategy and Commercial Opportunities for Tacrolimus Ointment

Last updated: August 11, 2026

Protopic is a topical tacrolimus ointment marketed by LEO Pharma in the United States and originally developed by Fujisawa, later Astellas. Its commercial value is tied to tacrolimus delivery through an anhydrous, occlusive ointment rather than to a complex device or biologic manufacturing process. The core opportunity is therefore formulation optimization: improving tolerability, cosmetic acceptability, stability, pediatric usability, and regulatory interchangeability while preserving topical exposure.

The branded product has faced generic erosion for years. New commercial opportunities are concentrated in differentiated tacrolimus formulations, pediatric and sensitive-skin products, private-label generic supply, excipient technology licensing, and combination products that improve adherence.

What is Protopic and what excipients does it contain?

Protopic contains tacrolimus, a topical calcineurin inhibitor approved for atopic dermatitis. The U.S. product is available in 0.03% and 0.1% strengths.

Product attribute	Protopic profile
Active ingredient	Tacrolimus
Dosage form	Topical ointment
Strengths	0.03% and 0.1%
U.S. indication	Moderate-to-severe atopic dermatitis in specified age groups
Original U.S. approval	2000
U.S. NDA	50777
Regulatory category	Small-molecule prescription drug
Primary vehicle	Anhydrous, occlusive ointment
Biosimilar pathway	Not applicable
Generic pathway	ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act

The U.S. label identifies the inactive ingredients as mineral oil, paraffin, propylene carbonate, white petrolatum, and white wax.[1] The excipient system performs four commercial and technical functions:

1. It dissolves or disperses tacrolimus in a hydrophobic vehicle.
2. It creates occlusion that increases hydration of the stratum corneum.
3. It supports drug release into diseased skin.
4. It protects the formulation from water-driven degradation and microbial growth.

Propylene carbonate is the principal polar solvent in the vehicle. The hydrocarbon components control viscosity, occlusion, spreadability, and residual skin feel. White wax contributes structure and rheology.

How does the Protopic excipient system work?

The formulation is designed around tacrolimus’ low aqueous solubility and high lipophilicity. A conventional aqueous cream would introduce greater risks of crystallization, phase separation, preservative dependence, and altered skin penetration.

Functional role of each excipient

Excipient	Primary formulation role	Commercial significance
Propylene carbonate	Solvent or cosolvent for tacrolimus	Controls drug solubilization and release
Mineral oil	Emollient and hydrophobic vehicle	Supports spreadability and occlusion
Paraffin	Rheology modifier and occlusive hydrocarbon	Controls consistency and residence time
White petrolatum	Main ointment base and barrier-forming agent	Provides skin protection and low water activity
White wax	Structuring agent	Improves firmness, temperature resistance, and package compatibility

The excipient system is commercially conservative but technically effective. Its main limitation is sensory performance. Patients may perceive the product as greasy, sticky, heavy, or difficult to remove. Burning and pruritus are also common early treatment complaints in tacrolimus ointment labeling, although these effects are principally associated with tacrolimus and skin inflammation rather than with one excipient alone.[1]

A reformulation that changes the solvent, reduces occlusivity, or introduces water must demonstrate that tacrolimus remains chemically stable and therapeutically available at the skin surface.

What formulation patents protect Protopic and tacrolimus ointment?

The original Protopic formulation was protected by patents covering topical tacrolimus compositions and related use claims. The principal commercial patent barriers expired years ago, allowing multiple generic tacrolimus ointments to enter the U.S. market.

Protection category	Current commercial relevance
Original tacrolimus ointment composition	Largely expired
Tacrolimus 0.03% and 0.1% strengths	Generic competition established
Atopic dermatitis method of use	Limited blocking value after generic entry
Basic hydrocarbon ointment vehicle	Weak protection unless tied to a new performance result
New delivery system	Potentially protectable through formulation and method claims
New excipient combination	Potentially protectable if it produces non-obvious stability, release, or tolerability benefits
Manufacturing process	Potential value where it controls particle size, polymorph, uniformity, or drug loading

A commercial diligence review should distinguish between expired original patents, any surviving improvement patents, and patents listed for a specific NDA in the current FDA Orange Book. The existence of an old Protopic patent does not establish a current barrier to generic entry.[2]

How strong is the current Protopic patent estate?

The core patent estate is commercially weak because tacrolimus ointment has been genericized and the original composition is well known. Future strength would depend on narrower claims directed to:

• A defined tacrolimus particle-size distribution.
• A non-crystalline or controlled-crystallinity drug state.
• A specific solvent-to-hydrocarbon ratio.
• Reduced initial burning or improved tolerability.
• A low-grease emulsion or gel architecture.
• Improved delivery to eyelid, facial, pediatric, or intertriginous skin.
• A package that limits oxygen, moisture, or drug adsorption.
• A manufacturing process that produces a reproducible supersaturated system.

A patent directed only to replacing mineral oil with another emollient would face substantial obviousness risk unless the sponsor can establish an unexpected improvement in dermal delivery, stability, tolerability, or adherence.

When did Protopic lose exclusivity and when can generics launch?

Protopic lost the practical protection provided by its original U.S. exclusivity and patent estate in the early 2010s. FDA-approved generic tacrolimus ointments are now available in 0.03% and 0.1% strengths.

Milestone	Timing
FDA approval of Protopic	2000
Generic development under ANDA pathway	Began after applicable patent and exclusivity barriers
First broad generic entry	Early 2010s
Current market condition	Generic competition established
New generic launch risk	Primarily commercial, not patent-driven

What Paragraph IV challenges affected Protopic?

Paragraph IV certifications are relevant to generic applicants when an Orange Book-listed patent remains unexpired. Tacrolimus ointment has already experienced the relevant generic-entry cycle. The principal current risk is not a new Paragraph IV challenge to the original product. It is continued price pressure from approved ANDA products and additional generic suppliers.

A future tacrolimus product with a new formulation, new dosage form, or new delivery system could generate new Paragraph IV litigation if the sponsor lists eligible patents in the Orange Book. A generic applicant would then have to certify against those patents or wait for their expiration.

What is the Orange Book status of Protopic?

Protopic is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations under NDA 50777. The Orange Book is the controlling source for current patent listings, exclusivity codes, therapeutic-equivalence evaluations, and reference-product information.[2]

The commercial interpretation is straightforward:

• Protopic is an approved reference product.
• Tacrolimus ointment has an established ANDA pathway.
• Generic competition is available.
• The original product’s excipient system does not prevent ANDA approval.
• A new formulation with materially different excipients may require a separate 505(b)(2) strategy rather than a conventional ANDA.

An ANDA applicant generally must show pharmaceutical equivalence and bioequivalence. For topical products, FDA may require comparative clinical endpoint studies, pharmacodynamic studies, in vitro release testing, or other evidence depending on the product and guidance applicable at the time of filing.[3]

What excipient strategies create commercial opportunities?

The most attractive opportunities address the weaknesses of the original ointment without disrupting tacrolimus delivery.

1. Low-grease ointment systems

A lower-residue vehicle could improve use on the face, hands, scalp margins, and during daytime treatment. Candidate approaches include:

• Reduced petrolatum content.
• Alternative hydrocarbon blends.
• Structured oleogels.
• Silicone-compatible emollients.
• Ester-based emollients with controlled volatility.
• Lamellar anhydrous systems.

The main risk is reduced occlusion and altered tacrolimus release. A lower-grease product must demonstrate equivalent or clinically meaningful performance rather than only improved sensory attributes.

2. Emulsion and cream formulations

A water-in-oil or oil-in-water emulsion could improve cosmetic acceptability and washability. It may also support incorporation of humectants and barrier-repair ingredients.

The technical burden is higher because water introduces:

• Microbial control requirements.
• Preservative selection.
• pH control.
• Hydrolysis and oxidation risk.
• Phase stability concerns.
• Potential tacrolimus crystallization.

A cream product could command a premium if it improves adherence, but it would likely require a 505(b)(2) or other non-ANDA development strategy if it is not pharmaceutically equivalent to the reference ointment.

3. Solvent-system optimization

Propylene carbonate is a central design variable. A new solvent system could alter:

• Tacrolimus solubility.
• Skin partitioning.
• Initial drug release.
• Crystallization during storage.
• Burning or stinging.
• Compatibility with plastic tubes and laminated packaging.

Potential replacement or co-solvent systems include glycols, glycol ethers, selected alcohols, and specialty dermal solvents. Each option has regulatory and toxicological constraints, particularly for pediatric use and application to damaged skin.

4. Barrier-repair excipients

Atopic dermatitis products may incorporate ceramides, fatty acids, cholesterol, glycerol, or other barrier-supporting ingredients. These additions create a product-positioning opportunity but also complicate regulatory classification.

A tacrolimus product with barrier-repair excipients could be positioned as a prescription treatment for inflammation plus barrier dysfunction. Claims must remain within the approved drug indication unless supported by appropriate regulatory evidence.

5. Pediatric and sensitive-site formulations

Children, eyelid users, and patients applying product to the face are more sensitive to greasiness and burning. A formulation optimized for these populations could support premium pricing and specialist adoption.

Useful design targets include:

• Lower tack.
• Rapid rub-in.
• Reduced residue.
• Low odor.
• Small-dose delivery.
• Improved tube dispensing.
• Compatibility with frequent hand washing.
• Minimal excipient sensitization potential.

A pediatric strategy must evaluate exposure from repeated use, accidental ingestion, occlusion by clothing or diapers, and use on inflamed or eroded skin.

6. Packaging as part of the excipient strategy

Packaging can materially affect product performance. Tacrolimus ointment should be evaluated for:

• Drug adsorption to tube liners.
• Solvent migration.
• Water and oxygen ingress.
• Extractables and leachables.
• Dose uniformity after storage.
• Compatibility with metered dispensers.

Airless pumps and unit-dose systems could reduce contamination and improve dose control. They may support a differentiated product, although packaging changes can create new device-combination regulatory obligations.

How does Protopic compare with competing topical calcineurin inhibitors?

The closest branded comparator is pimecrolimus cream, marketed as Elidel. The products differ in dosage form, excipient architecture, and patient experience.

Attribute	Protopic	Elidel
Active ingredient	Tacrolimus	Pimecrolimus
Dosage form	Ointment	Cream
Strength	0.03% and 0.1%	1%
Vehicle profile	Anhydrous, occlusive	Emulsion cream
Cosmetic profile	Greasier and more occlusive	Generally lighter
Generic availability	Established	Generic competition also established
Main formulation opportunity	Improve skin feel without losing delivery	Improve potency, stability, and cream tolerability

Protopic has a technical advantage in occlusion and a commercial disadvantage in cosmetic acceptability. Elidel demonstrates that a cream architecture can support topical calcineurin inhibition, but it does not establish bioequivalence for tacrolimus.

What regulatory pathway applies to a new tacrolimus formulation?

The pathway depends on how closely the proposed product matches Protopic.

Product concept	Likely regulatory route
Same tacrolimus strength and equivalent ointment composition	ANDA
Same active ingredient with materially different vehicle	505(b)(2)
New dosage form, such as foam, gel, spray, or cream	Usually 505(b)(2)
Tacrolimus plus barrier-repair active ingredient	505(b)(2) or combination-drug pathway
Cosmetic-only barrier product without tacrolimus	Cosmetic or nonprescription pathway, depending on claims
New topical device for delivery	Drug-device combination review may apply

The critical development issue is whether excipient changes alter local bioavailability. Systemic pharmacokinetics alone may not adequately characterize topical equivalence. FDA’s product-specific expectations should be confirmed during development through pre-IND or other regulatory interaction.[3]

What manufacturing and intellectual-property barriers affect tacrolimus ointment?

Tacrolimus is a potent, low-dose active ingredient. Manufacturing risks center on content uniformity, dispersion, crystallization, and solvent control.

Key manufacturing controls

• Uniform tacrolimus distribution at 0.03% and 0.1%.
• Control of drug particle size and agglomeration.
• Prevention of precipitation during cooling.
• Defined mixing temperature and shear.
• Control of residual solvents.
• Tube-filling uniformity.
• Stability under accelerated and long-term conditions.
• Container-closure compatibility.

The most defensible manufacturing patents would claim a reproducible process linked to a measurable product attribute. A process patent with no demonstrated impact on stability, release, or uniformity would have limited commercial leverage.

Which companies are positioned to challenge or extend Protopic’s market?

The competitive field includes:

• Generic manufacturers selling tacrolimus ointment.
• Contract development and manufacturing organizations with semisolid capabilities.
• Specialty dermatology companies developing improved topical vehicles.
• Excipient suppliers with dermal delivery platforms.
• Companies developing nonsteroidal atopic dermatitis products.

The strongest commercial challengers are not likely to compete through another conventional petrolatum ointment. They are more likely to pursue a cleaner sensory profile, improved adherence, broader sensitive-site use, or a novel dosage form.

What licensing deals could support a tacrolimus excipient program?

A licensing strategy could combine three assets:

1. Tacrolimus drug-product know-how.
2. A proprietary dermal vehicle or solvent system.
3. A regulatory and commercial partner with dermatology distribution.

Potential deal structures include:

• Upfront payment for an exclusive vehicle license.
• Development milestones tied to formulation selection and clinical proof.
• Sales royalties for an approved 505(b)(2) product.
• Regional rights for Europe, North America, Japan, or emerging markets.
• Supply agreements for a proprietary excipient or premix.
• Co-development with a generic manufacturer seeking a differentiated product.

The most valuable licensable asset is a vehicle with repeatable superiority in tolerability or adherence and a clear regulatory route. A formulation that is merely “greener” or “natural” without improved clinical or commercial performance is unlikely to support strong licensing economics.

What revenue exposure and generic launch risks exist?

Protopic is a mature branded product with established generic substitutes. Revenue exposure is therefore concentrated in price erosion, formulary substitution, and loss of prescription share.

Risk	Impact
Additional generic entrants	Lower net price and pharmacy substitution
Generic price competition	Margin compression
Low patient adherence to greasy ointment	Reduced refill persistence
New nonsteroidal competitors	Specialist prescribing pressure
Premium reformulations	Potential share recovery if clinically differentiated
Pediatric and sensitive-site use	Opportunity for targeted brand positioning
Reimbursement restrictions	Reduced access to branded product

A new excipient strategy should be evaluated against the cost of development. A premium formulation must generate enough clinical or adherence value to offset the established low-cost generic baseline.

Key Takeaways

• Protopic is a tacrolimus ointment based on mineral oil, paraffin, propylene carbonate, white petrolatum, and white wax.
• Its core patent protection has expired, and generic tacrolimus ointment competition is established.
• The original excipient system is technically robust but has cosmetic and tolerability limitations.
• The strongest commercial opportunity is a differentiated tacrolimus formulation with lower grease, improved spreadability, better package performance, or enhanced pediatric usability.
• A materially different vehicle will likely require a 505(b)(2) strategy rather than a conventional ANDA.
• New patents should focus on defined excipient ratios, crystallization control, local delivery, tolerability, manufacturing parameters, or packaging compatibility.
• Tacrolimus is a small molecule, so biosimilar risk does not apply.
• The commercial case depends on measurable adherence, tolerability, or delivery benefits because conventional generic substitution is already entrenched.

FAQs About Protopic Excipient and Formulation Opportunities

Can a company launch a new tacrolimus cream through the ANDA pathway?

Usually not if the cream is materially different from the reference ointment. A new cream may require a 505(b)(2) application supported by comparative quality, safety, efficacy, and local-delivery data.

Which Protopic excipient is most important for tacrolimus solubility?

Propylene carbonate is the principal solvent-related component in the U.S. ointment. Its concentration and interaction with the hydrocarbon base can affect tacrolimus crystallization and release.

Can ceramides be added to a tacrolimus ointment?

Yes, technically, but the addition could change drug release, stability, rheology, and regulatory classification. A ceramide-containing product would need a defined regulatory and clinical strategy.

Is tacrolimus ointment suitable for an OTC product?

Protopic is a prescription drug. An OTC conversion would require a separate FDA review, consumer-use data, labeling changes, and evidence supporting safe self-selection and self-administration.

What is the most defensible patent strategy for a new tacrolimus vehicle?

A patent should link a defined vehicle or process to an unexpected result, such as lower burning, improved dermal delivery, reduced crystallization, longer stability, or higher treatment persistence.

References

1. U.S. Food and Drug Administration. (2023). Protopic (tacrolimus) ointment prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: ANDAs for certain highly purified synthetic peptides and topical dermatological drug products. FDA.
4. National Library of Medicine. (2024). DailyMed: Protopic tacrolimus ointment. U.S. National Library of Medicine.
5. European Medicines Agency. (2018). Protopic: EPAR product information. EMA.